
Halozyme Therapeutics shares dropped due to worries about slowing sequential revenue growth and a broader selloff in AI-related stocks. Despite this, the company reported a 44.5% year-over-year increase in royalty revenue to $341 million in Q3 and raised its 2026 non-GAAP diluted EPS guidance from $8.65-$9.00 to $8.75-$9.05. Halozyme's three drug delivery technologies and partnerships with major pharmaceutical firms contribute to its attractive risk/reward profile, making it a notable mid-cap biotech stock to watch.
Halozyme Therapeutics shares are down 2.91% on Pluang, trading at USD 93.01 as of Nov 20, 2026 01:41 WIB. The stock's market cap stands at $10.94 billion, reflecting ongoing investor caution despite the company's strong revenue growth and raised EPS guidance.